Lenvatinib demonstrates anti-tumor effects in colorectal cancer, suggesting a promising therapeutic option.
Lenvatinib exhibits potent anti-CRC activity with minimal systemic toxicity. Its therapeutic effects are mediated through ERK pathway inactivation, suppression of anti-apoptotic proteins, and induction of caspase-dependent apoptosis.
No takes yet. Share an insight, caveat, or question.
Kuo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: